收藏切换
Assessment of drug availability and policy optimization for rare disease in China
收藏切换
Rui LU1, Ye CHEN1, 2, Jixi DING1, 2, *
World Clinical Drug | 2024, 45(11) : 1117 - 1124
Less
收藏切换
World Clinical Drug | 2024, 45(11): 1117-1124
• Topic •
Assessment of drug availability and policy optimization for rare disease in China
Full
Rui LU1, Ye CHEN1, 2, Jixi DING1, 2, *
Affiliations
  • 1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
  • 2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
Published: 2024-11-10 doi: 10.13683/j.wph.2024.11.002
Outline
收藏切换
Objective

To evaluate the availability of drugs for rare disease treatment in China and to provide suggestions for optimizing the supply system for the treatment of rare diseases in China.

Methods

The current status of rare disease drugs in China was analyzed by accessing databases and literature, and the availability rate of these drugs in tertiary hospitals and the national collaborative network of hospitals for rare disease diagnosis and treatment was evaluated by using the World Health Organization/Health Action International standard survey method.

Results

There were only 176 drugs in the two batches of rare disease catalogs, and 54% of those diseases had no drugs. The average preparation rate of 47 negotiated rare disease drugs in tertiary hospitals and hospitals of rare disease diagnosis and treatment collaborative network in the agreement period of the 2023 medical insurance catalog was only 6% and 14%, respectively.

Conclusion

The low availability of rare disease drugs in China is mainly due to the lack of research and development motivation of pharmaceutical companies and the high cost of drug management in hospitals. It is recommended to optimize the identification criteria of the catalog and preferential policies to strengthen the guiding effect of the catalog on the therapeutic areas. And to give priority to the special policy inclination of the whole process of super-rare disease drugs to guide their research and development to the market. Meanwhile, to issue the list of drug innovations for rare diseases and set up a centralized pharmacy to establish a supply system centered on the collaborative network hospitals.

rare disease catalog  /  national basic medical insurance  /  availability
鲁瑞, 陈烨, 丁锦希. 中国罕见病治疗药物可获得性评估与政策优化. 世界临床药物, 2024 , 45 (11) : 1117 -1124 . DOI: 10.13683/j.wph.2024.11.002
Rui LU, Ye CHEN, Jixi DING. Assessment of drug availability and policy optimization for rare disease in China[J]. World Clinical Drug, 2024 , 45 (11) : 1117 -1124 . DOI: 10.13683/j.wph.2024.11.002
Year 2024 volume 45 Issue 11
19
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.11.002
  • Receive Date:2024-08-02
  • Online Date:2026-11-17
  • Published:2024-11-10
Article Data
Affiliations
History
  • Received:2024-08-02
Affiliations
    1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
    2.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.11.002
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT